Danaher Corporation (DHR)
NYSE: DHR · IEX Real-Time Price · USD
243.54
-1.25 (-0.51%)
At close: Jul 19, 2024, 4:00 PM
245.00
+1.46 (0.60%)
Pre-market: Jul 22, 2024, 5:38 AM EDT
Danaher Employees
Danaher had 63,000 employees as of December 31, 2023. The number of employees decreased by 18,000 or -22.22% compared to the previous year.
Employees
63,000
Change (1Y)
-18,000
Growth (1Y)
-22.22%
Revenue / Employee
$357,444
Profits / Employee
$69,873
Market Cap
180.39B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63,000 | -18,000 | -22.22% |
Dec 31, 2022 | 81,000 | 1,000 | 1.25% |
Dec 31, 2021 | 80,000 | 11,000 | 15.94% |
Dec 31, 2020 | 69,000 | 9,000 | 15.00% |
Dec 31, 2019 | 60,000 | -11,000 | -15.49% |
Dec 31, 2018 | 71,000 | 4,000 | 5.97% |
Dec 31, 2017 | 67,000 | 5,000 | 8.06% |
Dec 31, 2016 | 62,000 | -19,000 | -23.46% |
Dec 31, 2015 | 81,000 | 10,000 | 14.08% |
Dec 31, 2014 | 71,000 | 5,000 | 7.58% |
Dec 31, 2013 | 66,000 | 3,000 | 4.76% |
Dec 31, 2012 | 63,000 | 4,000 | 6.78% |
Dec 31, 2011 | 59,000 | 10,800 | 22.41% |
Dec 31, 2010 | 48,200 | 1,600 | 3.43% |
Dec 31, 2009 | 46,600 | -3,700 | -7.36% |
Dec 31, 2008 | 50,300 | 300 | 0.60% |
Dec 31, 2007 | 50,000 | 5,000 | 11.11% |
Dec 31, 2006 | 45,000 | 5,000 | 12.50% |
Dec 31, 2005 | 40,000 | 5,000 | 14.29% |
Dec 31, 2004 | 35,000 | 5,000 | 16.67% |
Dec 31, 2003 | 30,000 | 1,000 | 3.45% |
Dec 31, 2002 | 29,000 | 6,000 | 26.09% |
Dec 31, 2001 | 23,000 | -1,000 | -4.17% |
Dec 31, 2000 | 24,000 | 5,000 | 26.32% |
Dec 31, 1999 | 19,000 | 1,000 | 5.56% |
Dec 31, 1998 | 18,000 | 4,800 | 36.36% |
Dec 31, 1997 | 13,200 | 1,600 | 13.79% |
Dec 31, 1996 | 11,600 | 1,100 | 10.48% |
Dec 31, 1995 | 10,500 | 540 | 5.42% |
Dec 31, 1994 | 9,960 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
AbbVie | 50,000 |
Amgen | 26,700 |
DHR News
- 4 days ago - Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development - PRNewsWire
- 5 days ago - Danaher Releases 2024 Sustainability Report - PRNewsWire
- 10 days ago - Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening - PRNewsWire
- 13 days ago - Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer - PRNewsWire
- 27 days ago - Danaher Schedules Second Quarter 2024 Earnings Conference Call - PRNewsWire
- 4 weeks ago - Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics - PRNewsWire
- 4 weeks ago - Global Flow Cytometry Industry Outlook Report, 2024-2032: Market Dynamics, Technology Insights, Patent Analysis (2014-2024), and Profiles of Leading Players Including BD and Danaher - GlobeNewsWire
- 6 weeks ago - Danaher Appoints Martin Stumpe to New Role of Chief Data & Artificial Intelligence Officer - PRNewsWire